|
A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth Clinical research trials and A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth. A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth  A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth
A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth
For Condition: HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) , Glaxo Wellcome
Synopsis: To determine if intravenous (IV) and oral zidovudine (AZT) can be safely given to children aged 1 day to 3 months who were born to mothers with an HIV infection. Also to determine the correct dose of AZT for young children. Of a total of 908 pediatric AIDS cases, 78 percent have acquired HIV infection from a mother with HIV infection or at high risk for acquisition of HIV, and the number of cases in children is expected to increase over the next several years. AZT therapy may be effective in altering the course of the disease and decreasing the high mortality in these children. It is also possible that early intervention with AZT may prevent the establishment of HIV contracted before, during, or just after birth.
Details: Of a total of 908 pediatric AIDS cases, 78 percent have acquired HIV infection from a mother with HIV infection or at high risk for acquisition of HIV, and the number of cases in children is expected to increase over the next several years. AZT therapy may be effective in altering the course of the disease and decreasing the high mortality in these children. It is also possible that early intervention with AZT may prevent the establishment of HIV contracted before, during, or just after birth. The children entered in this study receive oral and IV AZT. The first 6 children receive 2 IV doses and 2 oral doses over a 2-week period, then 4 weeks of continuous oral dosing (4 doses per day). The remaining 12 children receive 1 IV dose and 1 oral dose followed by 6 weeks of oral AZT (4 doses per day) and a second IV dose at the end of the study. Each child is under the care of a specialist in pediatrics and has a physical examination and laboratory tests before starting AZT and 6 times while taking AZT to make sure the drug is not having a toxic effect on the child. A single cerebrospinal fluid (CSF) sample is taken from the last 12 children entering the study, so that the level of the AZT reaching the brain can be measured. The child returns to the hospital or clinic 4 weeks after the end of therapy to make sure that there are no delayed toxic effects.
Eligibility:
Study Type: Interventional, Treatment, Open Label, Pharmacokinetics Study
Minimum Age/Maximum Age: /3 Months
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Infant gestation period must have been = or > 36 weeks and birthweight must = or > 2000 grams. Active infection must not be present at the time of entry into the study although an HIV culture or P24 serum antigen determination must be obtained prior to study entry. The child must have a life expectancy greater than 3 months. Parents or guardian must be available to give informed consent. Prior Medication: Allowed on a case-by-case basis: - Some essential supportive therapies including antibiotics. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Any of the following laboratory findings within 2 weeks of study entry. - A total bilirubin > 2 times age-adjusted upper limit of normal. - Liver transaminase values > 3 x upper limit of normal. - Serum creatinine > 1.5 x upper limit of normal. - Total granulocyte count < 1500 cells/mm3. - Hemoglobin < 10 g/dl or hemoglobinopathy. - A urine toxicology screen positive for any drug or chemical. - Infants must not have hemoglobinopathy or active infection at entry. Prior Medication: Excluded within 2 months of study entry: - Antiretroviral agents. - Excluded within 4 weeks of study entry: - Immunomodulating agents including steroids, interferon, isoprinosine, and interleukin. - Immunoglobulin. - Excluded within 2 weeks of study entry: - Any other experimental therapy, drugs which cause prolonged neutropenia or significant nephrotoxicity, or rifampin / rifampin derivatives. - Some essential supportive therapies including antibiotics may have infrequent or transient effects. These drugs will be considered on a case-by-case basis. Prior Treatment: Excluded within 2 weeks of study entry: - Red blood cells or whole blood transfusion. - Excluded within 4 weeks of study entry: - Lymphocyte transfusions for immune reconstitution. Infants may not be entered into the study during the first 2 weeks of life if their mother received methadone therapy during the last trimester of her pregnancy or used any known illicit drug. A maternal urine toxicology screen may be optionally performed prior to entry of the child, and children whose mothers have a screen which is positive for any drugs or chemicals may not be enrolled within 2 weeks of the positive screen.
Total Enrollment: 18
Location and Contact Information:
Overall Study Official:
ModlinJ, Study Chair,
Johns Hopkins Hosp
Baltimore, Maryland, 21287
United States
Johns Hopkins Hosp - Pediatric
Baltimore, Maryland, 212874933
United States
Duke Univ Med Ctr
Durham, North Carolina, 277103499
United States
Boston Med Ctr
Boston, Massachusetts, 02118
United States
Univ of Alabama at Birmingham
Birmingham, Alabama, 35294
United States
Stanford Univ School of Medicine
Stanford, California, 94305
United States
Additional Information:
Study ID Numbers: ACTG 049; FDA 9D
Study Start Date:
Record last reviewed: January 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001007
Other Hiv Infections Studies:
1. Safety and Acceptability of PRO 2000 Vaginal Gel in HIV Uninfected Women in India
2. A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection
3. Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC
4. The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used with and without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs
5. Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients
Related Studies:
Other HIV Infections Clinical Trials
Other Maryland Clinical Trials
Other Baltimore Clinical Trials
A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth
|
|
|
|
|
|
|
|
